sunitinib vipharm 12,5mg tvrdá tobolka
vipharm s.a., ożarów mazowiecki array - 17468 sunitinib-malÁt - tvrdá tobolka - 12,5mg - sunitinib
sunitinib vipharm 25mg tvrdá tobolka
vipharm s.a., ożarów mazowiecki array - 17468 sunitinib-malÁt - tvrdá tobolka - 25mg - sunitinib
sunitinib vipharm 50mg tvrdá tobolka
vipharm s.a., ożarów mazowiecki array - 17468 sunitinib-malÁt - tvrdá tobolka - 50mg - sunitinib
sunitinib zentiva 12,5mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 12,5mg - sunitinib
sunitinib zentiva 25mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 25mg - sunitinib
sunitinib zentiva 37,5mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 37,5mg - sunitinib
sunitinib zentiva 50mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 50mg - sunitinib
therios 75 mg žvýkací tablety pro kočky 75 mg Žvýkací tableta
ceva santé animale - cefalexin - Žvýkací tableta - 75mg - první generace cefalosporinů - kočky
fatroximin topic 2.94 mg/g kožní sprej, roztok
fatro, s.p.a. - rifaximin - kožní sprej, roztok - jiná antibiotika pro lokální použití - kočky, koně, kozy, králíci, ovce, prasata, skot, psi
cosentyx
novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - imunosupresiva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriatická arthritiscosentyx, samostatně nebo v kombinaci s methotrexátem (mtx), je indikován pro léčbu aktivní psoriatické artritidy u dospělých pacientů, pokud odpověď na předchozí léčbu chorobu modifikující anti antirevmatickými léky (dmard) terapie byla nedostatečná. axiální spondylartritidy (axspa)ankylozující spondylitida (as, radiografické axiální spondylartritidy)cosentyx je indikován k léčbě aktivní ankylozující spondylitidy u dospělých, kteří nereagovali adekvátně na konvenční léčbu. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.